^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Waldenstrom Macroglobulinemia
    Drug:iopofosine I-131 (CLR 131) (Beta radiation emitter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Cellectar Biosciences Press Release
    Title:

    Cellectar Receives FDA Fast Track Designation for CLR 131 in Lymphoplasmacytic Lymphoma/Waldenstrom’s Macroglobulinemia

    Published date:
    05/26/2020
    Excerpt:
    Cellectar Bioscience...today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for CLR 131 in lymphoplasmacytic lymphoma (LPL)/Waldenstrom’s macroglobulinemia (WM) in patients having received two prior treatment regimens or more.